HomeAMRN • NASDAQ
Amarin Corporation PLC
add
In the news
Financials
Income Statement
Revenue
Net Income
Revenue
Net income
| (USD) | Mar 2025info | Y/Y change |
|---|---|---|
Revenue | 42.02M | -25.66% |
Operating expense | 41.89M | -7.92% |
Net income | -15.70M | -57.71% |
Net profit margin | -37.36 | -112.15% |
Earnings per share | -0.40 | -100.00% |
EBITDA | -16.00M | -24.81% |
Effective tax rate | -15.16% | — |
Balance Sheet
Total Assets
Total Liabilities
Total assets
Total liabilities
| (USD) | Mar 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 281.79M | -8.56% |
Total assets | 655.68M | -17.00% |
Total liabilities | 181.99M | -25.44% |
Total equity | 473.69M | — |
Shares outstanding | 20.67M | — |
Price to book | 0.47 | — |
Return on assets | -6.25% | — |
Return on capital | -8.57% | — |
Cash Flow
Net Change in Cash
Net change in cash
| (USD) | Mar 2025info | Y/Y change |
|---|---|---|
Net income | -15.70M | -57.71% |
Cash from operations | — | — |
Cash from investing | — | — |
Cash from financing | — | — |
Net change in cash | — | — |
Free cash flow | — | — |
Previous close
$10.71
Day range
$10.50 - $11.19
Year range
$7.08 - $19.10
Market cap
219.93M USD
Avg Volume
108.05K
About
Amarin Corporation is an Irish-American biopharmaceutical company founded in 1993 and headquartered in Dublin, Ireland and Bridgewater, New Jersey. The company develops and markets medicines for the treatment of cardiovascular disease. It has developed the drug Vascepa, a prescription grade omega-3 fatty acid.
In July 2012, their lead-candidate drug named Vascepa received FDA-approval, competing against GlaxoSmithKline's Lovaza. Wikipedia
Founded
Mar 1, 1989
Headquarters
Website
Employees
275
